1 / 27

Overview of Procurement and Supply Management Policies

Overview of Procurement and Supply Management Policies. Meeting of WHO Prequalification Programme with European manufacturers and EU marketing authorisation holders Copenhagen, November 2009 Carmen Perez Casas Pharmaceutical Management Unit. Presentation Outline. Global Fund grants

basil
Download Presentation

Overview of Procurement and Supply Management Policies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Overview of Procurement and Supply Management Policies Meeting of WHO Prequalification Programme with European manufacturers and EU marketing authorisation holders Copenhagen, November 2009 Carmen Perez Casas Pharmaceutical Management Unit

  2. Presentation Outline • Global Fund grants • Overview of procurement volumes by grantees • Quality assurance policy • Procurement and Supply Management Policy • Most frequently purchased medicines

  3. The Global Fund Extract of TGF Guiding principles : • Operate as a financial instrument , not implementing agency • Make available and leverage additional financial resources • Support programs that evolve from national plans and priorities • Performance-based funding mechanism “Making a “sustainable and significant” contribution to the achievement of the Millennium Development Goals” 678 grants in 140 countries (Nov. 09)

  4. Rapid scaling up of results Global Fund Top 3 result indicators (2009)

  5. Global Resources DistributionRounds 1-8, (July 2009) byRegions Expenditure Component (July 2009) Estimates from Rounds 2-8 proposals 100% = $8.2 billion USD 100% = US$ 15.9 billion % of total funds approved by the Board, including Phase 2 & RCC OP/140709/2

  6. Disease Components DistributionRounds 1-8, (July 2009) Global Fund Resources by Disease Component 100% = US$ 15.9 billion Percentages of total funds approved by the Board, including Phase 2 & RCC OP/140709/3

  7. Overview of procurement of medicines by value Data from 2006-2007

  8. The Global Fund Approach for procurement • Principles and minimum standards, not detailed procedures • Build upon existing systems • Principal Recipients responsible for all PSM activities • Even if contracted out Operational principles for Good Pharmaceutical Procurement.

  9. Policies and Principles • Quality-assured products • Lowest possible price • National laws and international agreements • Conduct procurement processes in a transparent and competitive manner Guide outlines what PRs need to do

  10. Procurement mechanisms PRs use own purchasing system, Or subcontract procurement agent mandatory in case insufficient capacity exist, most commonly used procurement agents : UNICEF, IDA, WHO PPS ... MDR-TBtreatment: mandatory Green Light Committee support services Voluntary Pooled Procurement and Capacity Building Services: Launched in June 2009 Affordable Medicine Facility for malaria (AMFm):Approved in November 2008

  11. QA Policy for Pharmaceutical Products “Global Fund resources may only be used to procure medicines that have been authorized for use by the NDRA in the recipient country in accordance with its standard practices for drug registration (or other forms of authorization)”

  12. QA Policy for Pharmaceutical Products • For medicines prequalified by the WHO PQ, NDRAs are encouraged to expedite the process for authorizing their use • by accepting the PQ approval letter and supporting documentation, including WHO PQ report and the manufacturer's summary of information relating to the quality, safety and efficacy • For medicines authorized for use by an SRA, NDRAs are encouraged to expedite the process for authorizing their use • by accepting the executive summary of the Common Technical Document for the Registration of Pharmaceutical Products for Human Use (CTD) or sections of the CTD relating to the quality, safety and efficacy • and all necessary information to perform quality control testing of products and necessary reference standards.

  13. QA policy for ARVs, antiTB and antimalarials Antiretrovirals, antituberculosis, and antimalarial pharmaceutical products can be purchased using Global Fund resources if they are, prequalified by the WHO Prequalification Programme, and/or authorized for marketing in a country with a stringent drug regulatory authority (SRA) (registration "for export only" is not sufficient), or

  14. QApolicy for ARVs, antiTB and antimalarials for products marketed exclusively outside ICH region, approved or subject to a positive opinion under one of the following schemes: Canada S.C. 2004, c. 23 (Bill C-9) procedure (HIV medications), Art. 58 of European Union Regulation (EC9 No. 726/2004) , US-FDA tentative approval (ARVS) or

  15. QA policy for ARVs, antiTB and antimalarials if there are <2 products available on the market from previous categories (WHO prequalified or registered by a SRA), Alternative products can accepted for purchase by the Global Fund based on the recommendation of an independent panel of technical experts (ERP) independent technical body hosted by WHO

  16. QA Policy for Procurement of All Other Pharmaceuticals All FPPs, other than ARVs, anti-TB and antimalarials, need only to comply with the relevant quality standards that are established by the National Drug Regulatory Authority (NDRA) in the country of use PRs must ensure that all FPPs are procured in accordance with principles set forth in the Interagency Guidelines: “A Model Quality Assurance System for Procurement Agencies “ (WHO, 2006)

  17. Monitoring quality product Manufacturers must provide methods used for quality control of products not published in pharmacopoeia

  18. Which medicines can be procured? Medicines listed in WHO or national or institutional Standard Treatment Guidelines or essential medicines list grant applicants or PRs to provide technical justification for selection of unlisted products in one of the STGs

  19. Which medicines are procured? Tuberculosis WHO PQ EOI First line medicines: Single ingredient products Fixed dose combinations Second-line TB medicines : procured through the Green Light Committee Plus Adjunctive therapies in MDR-TB treatment: Low volumes Nutritional support Corticosteroids Medicines for management of side effects

  20. GUIDELINES FOR THE PROGRAMMATIC MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS, WHO 2006 (2008)

  21. GUIDELINES FOR THE PROGRAMMATIC MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS, WHO 2006 (2008)

  22. Which medicines are procured? AIDS Antiretrovirals Medicines to treat HIV/AIDS related conditions: Mainly those listed in WHO-PQ EOI Some additions depending on country: Methadone and buprenorphine Metronizadole Amoxicillin, erythromycin, cloxacillin

  23. Medicines to treat HIV/AIDS related conditions, WHO PQ, EOI July 2009

  24. Which medicines are procured? Malaria WHO PQ EOI ACTs Artemisinin-based single-ingredient formulations Artemether, oily injection Artesunate, powder for injection Artesunate, suppositories Artesunate, tablet* * GF discourages the use of Artemisnin-based monotherapy products

  25. Other antimalarial medicines Mefloquine, tablet 250 mg Sulfadoxine + Pyrimethamine, tablet 500 mg + 25 mg Amodiaquine tablet 153 mg (or 200 mg as hydrochloride) Some additions to those listed in WHO PQ EOI : Quinine Di Hydrocloride 300mg/ml inj, or Sulphate 300mg tab Chloroquine 150mg tab Primaquine tab 15mg

More Related